Peptic ulcer within the past months prior to randomization, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) History of peptic ulcer disease within months of treatment. History within months prior to treatment of grade - gastrointestinal (GI) bleeding/hemorrhage, treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolus, or other uncontrolled thromboembolic event History of gastrointestinal bleeding, gastric stress ulcerations, or peptic ulcer disease within the past months prior to randomization that, in the investigator's opinion, may place the patient at risk of side effects from anti-angiogenesis products. Ongoing or active gastritis or peptic ulcer disease. Participant has active peptic ulcer disease or other hemorrhagic esophagitis/gastritis, enteritis, colitis. Active autoimmune disease including active diverticulitis, symptomatic peptic ulcer disease, colitis, or inflammatory bowel disease that has required systemic treatment in past years History of peptic ulcer within the past months prior to study treatment, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within days prior to study treatment Active peptic ulcer disease even if asymptomatic Patients with a history of peptic ulcer disease or gastrointestinal bleeding Active peptic ulcer disease for lesions within cm of the stomach History of peptic ulcer disease requiring treatment within the last -years Active peptic ulcer disease History of peptic ulcer disease or erosive gastritis within the past months, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within days of starting study treatment Patients must not have nor had active or recent peptic ulcer disease within the past months\r\n* Patients with active significant symptoms of dyspepsia will be excluded Active GI ulcer disease within weeks of study enrollment DONOR: Active peptic ulcer disease Ongoing or active gastritis or peptic ulcer disease. Active peptic ulcer disease defined as unhealed or clinically active Active gastritis or active peptic ulcer History within months prior to treatment of grade - gastrointestinal (GI) bleeding/hemorrhage, treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolus, or other uncontrolled thromboembolic event Subjects with history of anaphylaxis or angioedema, bronchial asthma, peptic ulcer\n and clinically significant food or drug allergy Patient must have no active peptic ulcer disease History of peptic ulcer within the past months of treatment, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within days of starting study treatment History of peptic ulcer disease within months of treatment, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within days of starting study treatment Clinically significant gastritis or peptic ulcer disease that would contraindicate the use of indomethacin. Active peptic ulcer disease even if asymptomatic Patients with history of gastrointestinal (GI) bleeding and peptic ulcer disease within the past months Malabsorption or uncontrolled peptic ulcer disease History of treatment-resistant peptic ulcer disease, erosive esophagitis, gastritis, or diverticulitis within months No discrete gastric or duodenal ulcer greater than mm within the past year except Helicobacter pylori-related peptic ulcer disease treated with antibiotics. History of peptic ulcer within the last months E . Any of the following within months prior to randomization: treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism, or other uncontrolled thromboembolic event. Active peptic ulcer disease Active peptic ulcer disease or other potentially hemorrhagic esophagitis/gastritis Uncontrolled inflammatory bowel disease, peptic ulcer disease or history of significant gastro intestinal bleeding within months of enrollment. History of perforation or bleeding related to peptic ulcer disease Active peptic ulcer History of intra-abdominal inflammatory process within months prior to Day of Cycle including but not limited to peptic ulcer disease, diverticulitis, or colitis Uncontrolled peptic or gastric ulcer disease, or gastrointestinal bleeding within prior months Any of the following within months prior to study entry: grade - gastrointestinal bleeding/hemorrhage, treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism or other uncontrolled thromboembolic event Subject has active peptic ulcer disease or other hemorrhagic esophagitis/gastritis No active peptic ulcer disease History of peptic ulcer disease or hemorrhagic gastritis within months of TRC administration, unless patient has received adequate treatment for peptic ulcer disease or hemorrhagic gastritis and has evidence of complete resolution documented by esophagogastroduodenoscopy (EGD); mild gastritis is allowed Patients with a history of peptic ulcer disease Patients with bradycardia, seizure disorder or peptic ulcer disease (PUD) EXCLUSION - STUDY : Active foot ulcer Will exclude patients with current, active peptic ulcer disease Gastrointestinal obstruction or an active peptic ulcer . Participant has active peptic ulcer disease or other hemorrhagic esophagitis/gastritis. Patient condition associated with a high risk of bleeding such as recent surgery or peptic ulcer disease Active peptic ulcer disease or evidence of gastrointestinal bleed Patients with active peptic ulceration Active peptic ulcer disease History of aspirin intolerance, bleeding diathesis, peptic ulcer or gastrointestinal bleed, endoscopic complications, or contraindication to colonoscopy Individuals with active gastroduodenal ulcer disease in the preceding years History of endoscopically or radiographically diagnosed peptic ulcer disease with upper GI bleeding during the past years or history of endoscopically or radiographically diagnosed peptic ulcer disease with upper GI bleeding any time while taking aspirin Prior history of gastrointestinal (GI) perforation, diverticulitis, and/or peptic ulcer disease No active peptic ulcer disease Have a history of peptic ulcer disease within the last months unless adequately treated as assessed by the participants primary care physician or medical oncologist History of peptic ulcer disease or erosive gastritis within the past months, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within days of starting study treatment